The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th international congress on antiphospholipid antibodies technical task force …

MM Abreu, A Danowski, DG Wahl, MC Amigo… - Autoimmunity …, 2015 - Elsevier
The purpose of this task force was to critically analyze nine non-criteria manifestations of
APS to support their inclusion as APS classification criteria. The Task Force Members …

Diagnosing antiphospholipid syndrome:'extra-criteria'manifestations and technical advances

S Sciascia, MC Amigo, D Roccatello… - Nature Reviews …, 2017 - nature.com
First described in the early 1980s, antiphospholipid syndrome (APS) is a unique form of
acquired autoimmune thrombophilia in which patients present with clinical features of …

Development of a new international antiphospholipid syndrome classification criteria phase I/II report: generation and reduction of candidate criteria

M Barbhaiya, S Zuily, Y Ahmadzadeh… - Arthritis care & …, 2021 - Wiley Online Library
Objective An international multidisciplinary initiative, jointly supported by the American
College of Rheumatology and European Alliance of Associations for Rheumatology, is …

The 2023 ACR/EULAR antiphospholipid syndrome classification criteria

M Barbhaiya, S Zuily, R Naden, A Hendry… - Arthritis & …, 2023 - Wiley Online Library
Objective To develop new antiphospholipid syndrome (APS) classification criteria with high
specificity for use in observational studies and trials, jointly supported by the American …

Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?

JA Gómez-Puerta, H Martín, MC Amigo, MA Aguirre… - Medicine, 2005 - journals.lww.com
We retrospectively studied a large cohort of patients with primary antiphospholipid syndrome
(APS) from 4 different referral centers to analyze the clinical and serologic features and …

First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo …

BA Pons-Estel, E Bonfa, ER Soriano… - Annals of the …, 2018 - ard.bmj.com
Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease,
represents a significant challenge for both diagnosis and treatment. Patients with SLE in …

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort

MF Ugarte-Gil, E Acevedo-Vásquez… - Annals of the …, 2015 - ard.bmj.com
Purpose To determine the association between the number of flares systemic lupus
erythematosus (SLE) patients experience and damage accrual, independently of other …

Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the “CAPS Registry”

B López-Benjume, I Rodríguez-Pintó, MC Amigo… - Autoimmunity …, 2022 - Elsevier
Objectives To describe the real-world experience of eculizumab use in patients with
catastrophic antiphospholipid syndrome (CAPS) according to the information provided by …

Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases

LJ Jara, G Medina, O Vera-Lastra, MC Amigo - Autoimmunity reviews, 2006 - Elsevier
Atherosclerosis (AT) is a chronic autoimmune inflammatory disease, characterized by
lipoproteins metabolism alteration leading to formation of pro-inflammatory and pro …

Ocular vaso-occlusive disease in primary antiphospholipid syndrome

C Castañón, MC Amigo, JL Bañales, A Nava… - Ophthalmology, 1995 - Elsevier
Purpose: To evaluate the ocular involvement in patients with the primary antiphospholipid
syndrome. Methods: The authors performed a cross-sectional ophthalmologic study of 17 …